|
Sequential WOMAC A Scores – Pain |
||||||
| Group |
Baseline |
Week 1 |
Week 2 |
Week 4 |
Week 6 |
Week 8 |
|
|
||||||
| Placebo |
8.7 ± 1.0 |
8.9 ± 1.1 |
8.5 ± 1.2 |
8.4 ± 1.2 |
6.8 ± 1.1 * |
6.3 ± 1.2 * |
| A |
9.1 ± 1.2 |
8.1 ± 1.2 * |
7.5 ± 1.2 ** |
6.5 ± 1.2 ** |
6.4 ± 1.2 ** |
6.3 ± 1.1 ** |
| B |
8.0 ± 1.1 |
7.5 ± 1.1 |
6.9 ± 1.1 ** |
5.7 ± 1.0 ** |
5.6 ± 1.1 ** |
5.0 ± 0.9 ** |
| C |
8.7 ± 1.0 |
8.0 ± 1.0b |
6.9 ± 0.9 *** |
5.6 ± 0.8 *** |
5.0 ± 0.8 *** |
4.3 ± 0.7 *** |
|
Data expressed as mean ± sem. Group A = High dose sierrasil (n = 20), Group B = Low dose sierrasil (n = 21), Group C = Low dose sierrasil + cat's claw extract (n = 25), placebo n = 22. All groups displayed a significant change over the 8 weeks of the study (p < 0.001, ANOVA). Using the Wilcoxan Matched-Pairs Signed-Rank test the following descriptors reflect statistical significance from baseline; * p < 0.05, ** p < 0.01, *** p < 0.001. | ||||||
Miller et al. Journal of Inflammation 2005 2:11 doi:10.1186/1476-9255-2-11 |
||||||